Commentary: Petrosal Vein Involvement in Neurovascular Conflict in Trigeminal Neuralgia: Surgical Technique and Clinical Outcomes

2021 ◽  
Author(s):  
André Beer-Furlan
2016 ◽  
Vol 23 (3) ◽  
pp. 309-316 ◽  
Author(s):  
Lucas Minig ◽  
Pablo Padilla Iserte ◽  
Cristina Zorrero ◽  
Vanna Zanagnolo

2021 ◽  
Vol 37 (1) ◽  
pp. e51-e52
Author(s):  
David A. Porter ◽  
Raed J. Narvel ◽  
Robert Hassan ◽  
Charles J. Jordan ◽  
Gautam A. Yagnik

Author(s):  
Iulia Peciu-Florianu ◽  
Jean Régis ◽  
Marc Levivier ◽  
Michaela Dedeciusova ◽  
Nicolas Reyns ◽  
...  

AbstractTrigeminal nerve schwannomas (TS) are uncommon intracranial tumors, frequently presenting with debilitating trigeminal and/or oculomotor nerve dysfunction. While surgical resection has been described, its morbidity and mortality rates are non-negligible. Stereotactic radiosurgery (SRS) has emerged with variable results as a valuable alternative. Here, we aimed at reviewing the medical literature on TS treated with SRS so as to investigate rates of tumor control and symptomatic improvement. We reviewed manuscripts published between January 1990 and December 2019 on PubMed. Tumor control and symptomatic improvement rates were evaluated with separate meta-analyses. This meta-analysis included 18 studies comprising a total of 564 patients. Among them, only one reported the outcomes of linear accelerators (Linac), while the others of GK. Tumor control rates after SRS were 92.3% (range 90.1–94.5; p < 0.001), and tumor decrease rates were 62.7% (range 54.3–71, p < 0.001). Tumor progression rates were 9.4% (range 6.8–11.9, p < 0.001). Clinical improvement rates of trigeminal neuralgia were 63.5% (52.9–74.1, p < 0.001) and of oculomotor nerves were 48.2% (range 36–60.5, p < 0.001). Clinical worsening rate was 10.7% (range 7.6–13.8, p < 0.001). Stereotactic radiosurgery for TS is associated with high tumor control rates and favorable clinical outcomes, especially for trigeminal neuralgia and oculomotor nerves. However, patients should be correctly advised about the risk of tumor progression and potential clinical worsening. Future clinical studies should focus on standard reporting of clinical outcomes.


Sign in / Sign up

Export Citation Format

Share Document